A rare case of aggressive primary pulmonary synovial sarcoma: A case report

---

Case Report

Author Details : Chandra Prakash, Rajesh Jain, V S Haritha*

Volume : 7, Issue : 4, Year : 2021

Article Page : 224-226

https://doi.org/10.18231/j.ijmpo.2021.046

Suggest article by email

Get Permission

---

Abstract

Synovial sarcoma is a malignant mesenchymal tumour which mostly affects young adults and is mostly seen in extremities. Primary synovial sarcoma arising from the lung is rare, accounting for less than 0.5% of all lung carcinomas. Most commonly it arises from the lung followed by pleura and mediastinum. Primary pulmonary synovial sarcoma is an extremely aggressive malignant tumour that can invade adjacent organs and give distant metastasis. Histologically it is of two main types – monophasic and biphasic. IHC is a must for diagnosis following clinical examination and imaging. Here we report a case of an elderly male with right lung mass lesion infiltrating the visceral and mediastinal pleura. PET – computerized tomography (CT) guided biopsy was s/o synovial sarcoma monophasic type which was further confirmed by IHC. The multimodality treated for this includes wide resection, chemotherapy and radiotherapy. Synovial sarcoma is relatively chemosensitive though it is considered as a high grade tumour with a poor prognosis. Because of the advanced stage of the disease our patient was not a candidate for surgery and was taken up for chemotherapy. He had a survival of 6 months but had succumbed due to non – cancer related cause.
 

Keywords: Synovial sarcoma, Lung, Rare, Advanced, Aggressive, Immunohistochemistry

How to cite : Prakash C, Jain R, Haritha V S, A rare case of aggressive primary pulmonary synovial sarcoma: A case report. IP Int J Med Paediatr Oncol 2021;7(4):224-226

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.